Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colesevelam + simvastatin is a combination therapy used to lower elevated cholesterol levels, particularly low-density lipoprotein cholesterol (LDL-C), in patients with hypercholesterolemia. Colesevelam is a bile acid sequestrant that binds bile acids in the intestine, preventing their reabsorption and promoting increased clearance of LDL-C from the blood. Simvastatin is an HMG-CoA reductase inhibitor (statin) that blocks the rate-limiting step in cholesterol biosynthesis, leading to reduced hepatic cholesterol synthesis and increased uptake of LDL by upregulating hepatic LDL receptors. The combination provides additive reductions in LDL-C compared to either agent alone and is well tolerated. This therapy may be used when monotherapy does not achieve target lipid levels or when additional lowering of LDL-C is desired[1][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colesevelam + simvastatin.